Contact   |    Careers   |    Employees   |    Physicians





Research - Research Trials

Open Research Trials at Sibley Memorial Hospital

Please contact Amanda Moser at (202) 660-6420 or by email to learn about the clinical trials offered at Sibley. 

Updated: February 2, 2015

Breast Cancer  

A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
Johns Hopkins Breast Cancer Program Longitudinal Repository
Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database
J1232 (DIG-HIF1 PK)
Digoxin as a Novel Inhibitor of Global Hypoxia Inducible Factor-1α (HIF-1α) Expression & Downstream Targets in Breast Cancer: DIG-HIF1 Pharmacodynamic Trial
J13104 (PBI)
A Randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with ER Negative Early Stage Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial RX for Positive Node, Endocrine Responsive Breast Cancer
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2-Directed Regimens in the Metastatic Setting

A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

Combination immunotherapy with Herceptin and the HER2 vaccine E75 in low and intermediate HER2-expressing breast cancer patients to prevent recurrence

Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

Detection and Prevention of Anthracycline-Related Cardiac Toxicity with Concurrent Simvastatin

A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer 

Correlation of Early Changes in SUV on PET with Pathological CR to Pertuzumab and Trastuzumab in Primary Operable HER2-Pos Breast Cancer 

J1377 (ATEMPT)
A Randomized Phase II Study of Adjuvant Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination with Trastuzumab for Stage I HER2-positive Breast Cancer
Gastrointestinal Cancer  

CALGB 80702
A Phase III trials of 6 versus 12 treatment of Adjuvant Treatment of Adjuvant  Folfox plus Celecoxib or Placebo for patient with Resected Stage III Colon Cancer


PROSPECT: A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision

Genitourinary Cancer  

Stereotactic Body Radiation Therapy and Short-Term Androgen Ablation for Intermediate-Risk, Localized, Adenocarcinoma of the Prostate
A Randomized Gene Fusion Stratified Phase 2 Trial Of Abiraterone With Or Without ABT 888 For Patients With Metastatic Castration-Resistant Prostate Cancer (NCI# 9012)
J1262 (Biopsy)
Understanding Mechanisms of Response and Resistance to Androgen-Directed Therapies in Men with Advanced Prostate Cancer Through Interrogation of Tumor Biopsies: A Pilot/Feasibility Study
Development and Evaluation of Tumor Markers for Clinically Significant Prostate Cancer
Immune Evaluation Study of Sipuleucel-T in African American and European American Men with Castrate Resistant Prostate Cancer
A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy TAK-700 With Androgen Deprivation Therapy Bicalutamide in Patients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
J1315 (ARN-509-003)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer

J1332 (LCCC-1231)
Observational Longitudinal Study of Pain in Men with Metastatic Castrate-Resistant Prostate Cancer
Abiraterone alone, abiraterone plus degarelix, a GnRH antagonist, and degarelix alone for prostate ca w/ rising PSA or a rising PSA and nodal disease following definitive radical prostatectomy
Race as a Risk Factor for Metastatic Prostate Cancer: A Sentinel Event Case Series


A Phase II Study to Determine Sequential Response to Bipolar Androgen Therapy (BAT) followed by Enzalutamide or Abiraterone Post-BAT in Men with Prostate Cancer Progressing on Combined Androgen Ablative Therapies

Phase III Trial of Enzalutamide (NSC # 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer

Active Surveillance of Prostate Cancer

A biospecimen bank and study to understand genitourinary cancer and other benign urologic conditions.

Gynecologic Cancer  

GOG 0263
A Randomized Phase III Clinical  Trial of  Adjuvant Radiation Versus Chemoradiation  In Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy. 
GOG 0238
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin In Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
GOG 0277
A Phase III Randomized Trial of Gemcitabine plus Docetaxel Followed by Doxorubicin versus Observation for Uterus-Limited High-Grade Uterine Leiomyosarcoma

Concurrent Chemotherapy and Pelvic RT w/wo Adj Chemo in High-Risk Pts with Early-Stage Cervical Ca following Radical Hysterectomy 

Kidney Cancer

ECOG 1808

A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features

Lung Cancer  

ECOG 5508
Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC 

Amgen: Evaluate the Long-Term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects w/ Advanced Stage NSCLC Receiving Multi-Cycle Chemo

There are no open studies at this time.


There are no open studies at this time.

© Copyright 2014 Sibley Memorial Hospital